Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

NCT00866619 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00866619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2009
Completion date
January 31, 2014
Enrollment
15,459 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

malaria